Bicocca Open Archive

Logo unimib boa
FONTANA, DILETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.709
AS - Asia 3.678
EU - Europa 3.395
SA - Sud America 622
AF - Africa 71
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 7
Totale 12.495
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.583
SG - Singapore 1.298
IT - Italia 1.099
CN - Cina 798
VN - Vietnam 668
DE - Germania 605
RU - Federazione Russa 512
BR - Brasile 495
HK - Hong Kong 423
IE - Irlanda 274
SE - Svezia 256
GB - Regno Unito 156
FR - Francia 101
ID - Indonesia 84
FI - Finlandia 81
IN - India 76
CA - Canada 71
KR - Corea 68
UA - Ucraina 65
TR - Turchia 54
AR - Argentina 52
PL - Polonia 41
BD - Bangladesh 40
IQ - Iraq 40
JP - Giappone 40
AT - Austria 39
ES - Italia 37
MX - Messico 37
NL - Olanda 32
ZA - Sudafrica 31
BE - Belgio 22
EC - Ecuador 22
DK - Danimarca 21
PK - Pakistan 17
CZ - Repubblica Ceca 16
PE - Perù 15
IR - Iran 12
LT - Lituania 12
CO - Colombia 11
MA - Marocco 11
VE - Venezuela 11
SA - Arabia Saudita 10
NZ - Nuova Zelanda 7
CH - Svizzera 6
EG - Egitto 6
KE - Kenya 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
EU - Europa 5
KG - Kirghizistan 5
NO - Norvegia 5
UY - Uruguay 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
CL - Cile 4
ET - Etiopia 4
NP - Nepal 4
PA - Panama 4
TN - Tunisia 4
AM - Armenia 3
BN - Brunei Darussalam 3
CI - Costa d'Avorio 3
IL - Israele 3
JO - Giordania 3
NI - Nicaragua 3
RO - Romania 3
BG - Bulgaria 2
BM - Bermuda 2
DO - Repubblica Dominicana 2
GR - Grecia 2
HN - Honduras 2
JM - Giamaica 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MY - Malesia 2
PH - Filippine 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
BO - Bolivia 1
BW - Botswana 1
CY - Cipro 1
DZ - Algeria 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LY - Libia 1
MM - Myanmar 1
MU - Mauritius 1
OM - Oman 1
PR - Porto Rico 1
QA - Qatar 1
SC - Seychelles 1
TG - Togo 1
TO - Tonga 1
Totale 12.494
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.055
Singapore 737
Ashburn 542
Milan 424
Hong Kong 417
Frankfurt am Main 393
Dublin 271
Chandler 224
Ho Chi Minh City 205
Dallas 197
Wilmington 172
Fairfield 167
Hanoi 157
Hefei 151
New York 150
Beijing 149
Los Angeles 135
Houston 130
Santa Clara 112
Dearborn 91
Munich 84
Woodbridge 84
Seattle 69
Jakarta 67
Seoul 62
Shanghai 61
Princeton 56
São Paulo 55
The Dalles 52
Cambridge 45
Moscow 45
Buffalo 43
Jacksonville 39
Chicago 37
Kent 36
Helsinki 35
Boyds 31
Altamura 30
Da Nang 30
Nuremberg 30
Nanjing 29
Guangzhou 28
Warsaw 28
Tokyo 27
Lawrence 26
Johannesburg 25
Kirkuk 23
Turku 23
Vienna 23
Haiphong 22
Monza 22
Dong Ket 21
London 21
Poplar 20
Sesto San Giovanni 19
Biên Hòa 18
Boardman 18
Desio 18
Hải Dương 18
Orem 18
Romola 18
Chennai 17
Denver 17
Montreal 17
Rome 17
Stockholm 17
Toronto 17
Brussels 16
Atlanta 15
Ha Long 15
Kocaeli 15
Pavia 15
Tianjin 15
Turin 15
Carate Brianza 14
Genoa 14
Phoenix 14
San Diego 14
Ankara 13
Belo Horizonte 13
Lappeenranta 13
Boston 12
Lissone 12
Meda 12
Ottawa 12
Rio de Janeiro 12
Salt Lake City 12
Council Bluffs 11
Düsseldorf 11
Fremont 11
Nanchang 11
Thái Nguyên 11
Amsterdam 10
Andover 10
Lauterbourg 10
Lima 10
Mexico City 10
Ninh Bình 10
Pune 10
Bari 9
Totale 7.844
Salva come PNG Salva come JPEG
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 513
Characterization of the role of mutated ETNK1 in the onset of atypical Chronic Myeloid Leukemia 410
Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2-ALK inhibition 401
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 399
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 395
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 377
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 363
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 360
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 357
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 313
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 310
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 310
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 309
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 306
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 302
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 285
Idiopathic erythrocytosis: a germline disease? 276
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 269
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 269
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 249
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 244
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 237
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 234
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 228
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 224
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 222
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 219
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 215
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 212
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 199
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 198
Clonal evolution analysis identifies ETNK1 as an early event and SETBP1 as a late event in atypical Chronic Myeloid Leukemia 195
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 185
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review 184
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 184
Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage 184
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 176
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 166
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 163
Role of somatic ETNK1 mutation in the mitochondrial activity 153
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 152
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 148
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 147
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 146
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 143
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape 140
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 138
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 137
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 134
Integrating mutational profiles and single-cell transcriptional data using LASSO regularized regression to elucidate key molecular functions involved in the pathogenesis of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with neutrophilia 124
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 119
miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia 117
ETNK1 mutations increase mitochondrial activity and promote DNA damage through ROS production 113
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 109
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 100
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia 99
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer 57
Totale 12.918
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.051
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.051
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021877 0 0 0 0 0 114 182 128 110 108 124 111
2021/2022651 84 88 79 61 36 59 21 20 30 43 56 74
2022/20231.152 108 271 124 104 110 152 18 62 64 34 32 73
2023/20241.216 46 43 64 76 122 276 235 36 105 52 51 110
2024/20253.188 149 284 170 172 254 120 222 114 334 576 285 508
2025/20264.201 1.169 544 612 880 704 292 0 0 0 0 0 0
Totale 12.918